Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer.

被引：0
|
作者：
Le, T [1 ]
Baines, KA [1 ]
Rambout, L [1 ]
Rezaifer, P [1 ]
Al Hayki, M [1 ]
Hopkins, L [1 ]
Fung, MFK [1 ]
机构：
[1] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：488S / 488S
页数：1
相关论文
共 50 条
  • [31] Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients
    Mads Kingo Guldberg Hansen
    Maja Patricia Smerdel
    Marianne Waldstrøm
    Rikke Fredslund Andersen
    Parvin Adimi
    Anders Jakobsen
    Karina Dahl Steffensen
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 751 - 759
  • [32] Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients
    Hansen, Mads Kingo Guldberg
    Smerdel, Maja Patricia
    Waldstrom, Marianne
    Andersen, Rikke Fredslund
    Adimi, Parvin
    Jakobsen, Anders
    Steffensen, Karina Dahl
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (06) : 751 - 759
  • [33] Weekly topotecan for recurrent platinum resistant ovarian cancer
    Abushahin, Fadi
    Singh, Diljeet K.
    Lurain, John R.
    Grendys, Edward C.
    Rademaker, Alfred W.
    Schink, Julian C.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 53 - 57
  • [34] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.
    Garcia, Agustin A.
    Hays, John L.
    Cote, Gregory Michael
    Becerra, Carlos
    Langleben, Adrian
    Lau, Susie K.
    Roman, Lynda D.
    McCormick, Colleen Catherine
    Richards, Donald A.
    Braiteh, Fadi S.
    Yimer, Habte Aragaw
    Richey, Stephen Lane
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Platinum compounds and paclitaxel in advanced epithelial ovarian cancer
    Gadducci, A
    Brunetti, I
    Cosio, S
    Giannessi, PG
    Genazzani, AR
    Conte, P
    ANTICANCER RESEARCH, 1997, 17 (6D) : 4703 - 4708
  • [37] PHASE 2 TRIAL OF DOSE DENSE (WEEKLY) PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R.
    Dorman, D.
    Lee, J.
    Apte, S.
    Chon, H.
    Shahzad, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 877 - 877
  • [38] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [39] Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer
    De Placido, S
    Tramontana, S
    Ferrari, E
    De Matteis, A
    Lauria, R
    Perrone, F
    Bianco, AR
    Gallo, C
    Ricchi, P
    De Placido, G
    Pignata, S
    ANTICANCER RESEARCH, 2000, 20 (5C) : 4023 - 4029
  • [40] Circulating periostin as a potential biomarker to predict platinum-resistant epithelial ovarian cancer.
    Ryner, Lisa
    Noyes, Amy
    Nazzal, Denise
    Vu, Paul
    Guan, Yinghui
    Lu, Shan
    Morimoto, Alyssa
    Brignoli, Sue
    Wang, Yulei
    CLINICAL CANCER RESEARCH, 2016, 22
12345